Cargando…

Sarilumab: patient-reported outcomes in rheumatoid arthritis

In the last few decades, strategies for the management of rheumatoid arthritis (RA) have been increasingly oriented toward more comprehensive control of the disease, taking into account even RA extra-articular manifestations, comorbidities, and the patient’s perception about the disease. The need fo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Crotti, Chiara, Biggioggero, Martina, Becciolini, Andrea, Favalli, Ennio Giulio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2018
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6108331/ https://www.ncbi.nlm.nih.gov/pubmed/30154675 http://dx.doi.org/10.2147/PROM.S147286

Ejemplares similares

Profile of sarilumab and its potential in the treatment of rheumatoid arthritis
por: Raimondo, Maria Gabriella, et al.
Publicado: (2017)

Tocilizumab in the treatment of rheumatoid arthritis: an evidence-based review and patient selection
por: Biggioggero, Martina, et al.
Publicado: (2018)

Spotlight on mavrilimumab for the treatment of rheumatoid arthritis: evidence to date
por: Crotti, Chiara, et al.
Publicado: (2017)

Upadacitinib and filgotinib: the role of JAK1 selective inhibition in the treatment of rheumatoid arthritis
por: Biggioggero, Martina, et al.
Publicado: (2019)

Structural integrity versus radiographic progression in rheumatoid arthritis
por: Favalli, Ennio Giulio, et al.
Publicado: (2015)

The role of methotrexate as combination therapy with etanercept in rheumatoid arthritis: Retrospective analysis of a local registry
por: Becciolini, Andrea, et al.
Publicado: (2016)

The role of concomitant methotrexate dosage and maintenance over time in the therapy of rheumatoid arthritis patients treated with adalimumab or etanercept: retrospective analysis of a local registry
por: Favalli, Ennio Giulio, et al.
Publicado: (2018)

The Management of Acute Anterior Uveitis Complicating Spondyloarthritis: Present and Future
por: Biggioggero, Martina, et al.
Publicado: (2018)

A review of the literature analyzing benefits and concerns of infliximab biosimilar CT-P13 for the treatment of rheumatologic diseases: focus on interchangeability
por: Becciolini, Andrea, et al.
Publicado: (2017)

Treatment Comparison in Rheumatoid Arthritis: Head-to-Head Trials and Innovative Study Designs
por: Favalli, Ennio Giulio, et al.
Publicado: (2014)

The Use of Rheumatic Disease Comorbidity Index for Predicting Clinical Response and Retention Rate in a Cohort of Rheumatoid Arthritis Patients Receiving Tumor Necrosis Factor Alpha Inhibitors
por: Biggioggero, Martina, et al.
Publicado: (2019)

Sarilumab monotherapy vs sarilumab and methotrexate combination therapy in patients with rheumatoid arthritis
por: Burmester, Gerd R, et al.
Publicado: (2021)

Population Pharmacokinetics of Sarilumab in Patients with Rheumatoid Arthritis
por: Xu, Christine, et al.
Publicado: (2019)

Damage progression in rheumatoid arthritis: the role of biologic agents
por: Favalli, Ennio Giulio
Publicado: (2012)

Disease–Drug Interaction of Sarilumab and Simvastatin in Patients with Rheumatoid Arthritis
por: Lee, Eun Bong, et al.
Publicado: (2016)

The impact of EMA recommendations on the real-life use of Janus kinases inhibitors for rheumatoid arthritis: the Expanded Risk Score in RA as a tool to quantify the risk of cardiovascular events
por: Favalli, Ennio Giulio, et al.
Publicado: (2023)

Safety and tolerability of subcutaneous sarilumab and intravenous tocilizumab in patients with rheumatoid arthritis
por: Emery, Paul, et al.
Publicado: (2019)

Clinical evaluation of the safety, efficacy and tolerability of sarilumab in the treatment of moderate to severe rheumatoid arthritis
por: Pelechas, Eleftherios, et al.
Publicado: (2019)

Sarilumab improves patient-reported outcomes in rheumatoid arthritis patients with inadequate response/intolerance to tumour necrosis factor inhibitors
por: Strand, Vibeke, et al.
Publicado: (2017)

Two years of sarilumab in patients with rheumatoid arthritis and an inadequate response to MTX: safety, efficacy and radiographic outcomes
por: Genovese, Mark C, et al.
Publicado: (2018)

The Impact of Anti-rheumatic Drugs on the Seroprevalence of Anti-SARS-CoV-2 Antibodies in a Cohort of Patients With Inflammatory Arthritis: The MAINSTREAM Study
por: Favalli, Ennio Giulio, et al.
Publicado: (2022)

Corrigendum: The Impact of Anti-rheumatic Drugs on the Seroprevalence of Anti-SARS-CoV-2 Antibodies in a Cohort of Patients With Inflammatory Arthritis: The MAINSTREAM Study
por: Favalli, Ennio Giulio, et al.
Publicado: (2022)

Understanding the Role of Interleukin-6 (IL-6) in the Joint and Beyond: A Comprehensive Review of IL-6 Inhibition for the Management of Rheumatoid Arthritis
por: Favalli, Ennio G.
Publicado: (2020)

Subcutaneous Sarilumab in Patients With Rheumatoid Arthritis who Previously Received Subcutaneous Sarilumab or Intravenous Tocilizumab: An Open‐Label Extension of a Randomized Clinical Trial
por: Emery, Paul, et al.
Publicado: (2020)

Baricitinib for COVID-19: a suitable treatment?
por: Favalli, Ennio G, et al.
Publicado: (2020)

Patient-reported outcomes from a randomized phase III trial of sarilumab monotherapy versus adalimumab monotherapy in patients with rheumatoid arthritis
por: Strand, Vibeke, et al.
Publicado: (2018)

Combination Therapy with Nintedanib and Sarilumab for the Management of Rheumatoid Arthritis Related Interstitial Lung Disease
por: Vacchi, Caterina, et al.
Publicado: (2020)

Disproportionate articular pain is a frequent phenomenon in rheumatoid arthritis and responds to treatment with sarilumab
por: Choy, Ernest, et al.
Publicado: (2022)

Long-term safety and efficacy of sarilumab with or without background csDMARDs in rheumatoid arthritis
por: Burmester, Gerd R, et al.
Publicado: (2023)

COVID-19 infection and rheumatoid arthritis: Faraway, so close!
por: Favalli, Ennio Giulio, et al.
Publicado: (2020)

Safety and efficacy of switching from adalimumab to sarilumab in patients with rheumatoid arthritis in the ongoing MONARCH open-label extension
por: Burmester, Gerd R, et al.
Publicado: (2019)

Impact of corticosteroids and immunosuppressive therapies on symptomatic SARS-CoV-2 infection in a large cohort of patients with chronic inflammatory arthritis
por: Favalli, Ennio Giulio, et al.
Publicado: (2020)

Sarilumab plus methotrexate improves patient-reported outcomes in patients with active rheumatoid arthritis and inadequate responses to methotrexate: results of a phase III trial
por: Strand, Vibeke, et al.
Publicado: (2016)

Identification of a Rule to Predict Response to Sarilumab in Patients with Rheumatoid Arthritis Using Machine Learning and Clinical Trial Data
por: Rehberg, Markus, et al.
Publicado: (2021)

Long-term safety of sarilumab in rheumatoid arthritis: an integrated analysis with up to 7 years’ follow-up
por: Fleischmann, Roy, et al.
Publicado: (2020)

Impact of IL6R genetic variants on treatment efficacy and toxicity response to sarilumab in rheumatoid arthritis
por: Sainz, Luis, et al.
Publicado: (2023)

Association between low hemoglobin, clinical measures, and patient-reported outcomes in patients with rheumatoid arthritis: results from post hoc analyses of three phase III trials of sarilumab
por: Rubbert-Roth, Andrea, et al.
Publicado: (2022)

Correction to: Identification of a Rule to Predict Response to Sarilumab in Patients with Rheumatoid Arthritis Using Machine Learning and Clinical Trial Data
por: Rehberg, Markus, et al.
Publicado: (2021)

Immunogenicity of Sarilumab Monotherapy in Patients with Rheumatoid Arthritis Who Were Inadequate Responders or Intolerant to Disease-Modifying Antirheumatic Drugs
por: Wells, Alvin F., et al.
Publicado: (2019)

Population Pharmacodynamic Model of Neutrophil Margination and Tolerance to Describe Effect of Sarilumab on Absolute Neutrophil Count in Patients with Rheumatoid Arthritis
por: Kovalenko, Pavel, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_gd4mnr8mjm7ooho61i7uasotbv